Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis

The study explored the potential of the retinoic acid receptor agonist Ch55 as an antifibrotic agent in the dermis. Ch55 was found to effectively downregulate fibrosis-associated genes and reduce collagen deposition in human foreskin fibroblasts, even in the presence of TGF-β1. In a preclinical rabbit ear hypertrophic scar model, Ch55 demonstrated antiscarring activity by decreasing scar hypertrophy and type I collagen levels. The research suggested that Ch55 could modulate pathways associated with fibrosis, indicating its potential as a therapeutic agent for treating dermal fibrosis. However, the study did not specify the number of participants, which is important for evaluating the robustness of the findings.